Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Stock: price and insider trades · China
莎普爱思
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.: what insiders have been doing
Every trade that managers of Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. The past year has been quiet: not a single insider filing for Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. The previous disclosure was published on 28 November 2022.
The full history, which starts in 2021, counts no purchases against 11 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 520,400 shares23.7% of flowA股XSHGSSE:173000006080675740
- 40,000 shares2.0% of flowA股XSHGSSE:173000006060669380
- 60,000 shares2.9% of flowA股XSHGSSE:173000006053479740
- 80,000 shares3.9% of flowA股XSHGSSE:173000006025322180
- 60,000 shares3.1% of flowA股XSHGSSE:173000005714677820
- 40,000 shares2.4% of flowA股XSHGSSE:173000005419071700
- 50,000 shares3.0% of flowA股XSHGSSE:173000005407443940
- 455,000 shares28.9% of flowA股XSHGSSE:173000005223711680
- 320,000 shares20.0% of flowA股XSHGSSE:173000005217206750
- 50,000 shares2.7% of flowA股XSHGSSE:173000005210424130
- 138,000 shares7.5% of flowA股XSHGSSE:173000005475694720
11 of 11 declarations
About Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.
莎普爱思 is a company operating in the health and pharmaceutical sector, listed on the XSHG market. It focuses on the development and marketing of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
